The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Original Article
Brief Report
PreviousPrevious
Volume 348:1342-1347 April 3, 2003 Number 14
NextNext

Infection with Vancomycin-Resistant Staphylococcus aureus Containing the vanA Resistance Gene
Soju Chang, M.D., M.P.H., Dawn M. Sievert, M.S., Jeffrey C. Hageman, M.H.S., Matthew L. Boulton, M.D., Fred C. Tenover, Ph.D., M.P.H., Frances Pouch Downes, Dr.P.H., Sandip Shah, M.S., James T. Rudrik, Ph.D., Guy R. Pupp, D.P.M., William J. Brown, Ph.D., Denise Cardo, M.D., Scott K. Fridkin, M.D., for the Vancomycin-Resistant Staphylococcus aureus Investigative Team

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-PubMed Citation
Until recently, vancomycin was the only uniformly effective treatment for staphylococcal infections. In 1997, the first clinical isolate of Staphylococcus aureus with reduced susceptibility to vancomycin was reported,1 and as of June 2002, eight confirmed infections with such strains had been reported in patients in the United States.2,3,4,5,6 The minimal inhibitory concentrations (MICs) of vancomycin reported for these isolates are in the intermediate range (8 to 16 µg per milliliter) according to interpretive criteria defined by the National Committee for Clinical Laboratory Standards.7

In June 2002, a clinical isolate of vancomycin-resistant S. aureus (VRSA) (MIC, >32 µg per milliliter) was . . . [Full Text of this Article]

Case Report

Methods

Results

Epidemiologic Studies

Laboratory Studies

Discussion


Source Information

From the Epidemic Intelligence Service, Division of Applied Public Health Training, Epidemiology Program Office (S.C.), and the Division of Healthcare Quality Promotion, National Center for Infectious Diseases (J.C.H., F.C.T., D.C., S.K.F.), Centers for Disease Control and Prevention, Atlanta; the Bureau of Epidemiology (D.M.S., M.L.B.) and the Bureau of Laboratories (F.P.D., S.S., J.T.R.), Michigan Department of Community Health, Lansing; Lakeview Podiatry Associates, Dearborn, Mich. (G.R.P.); and the Department of Pathology, Wayne State University School of Medicine and Detroit Medical Center University Laboratories, Detroit (W.J.B.).

Address reprint requests to Dr. Fridkin at the Centers for Disease Control and Prevention, 1600 Clifton Rd., Mailstop A-35, Atlanta, GA 30333, or at sfridkin@cdc.gov.


This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.